[对 PDGFRA 突变型胃肠道间质瘤生物学行为的再认识]。

W Yuan, W Huang, L Ren, H Y Liang, S Y Dong, X Y Du, C Xu, Y Fang, K T Shen, Y Y Hou
{"title":"[对 PDGFRA 突变型胃肠道间质瘤生物学行为的再认识]。","authors":"W Yuan, W Huang, L Ren, H Y Liang, S Y Dong, X Y Du, C Xu, Y Fang, K T Shen, Y Y Hou","doi":"10.3760/cma.j.cn112151-20230908-00153","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> To investigate the biological behavior spectrum of platelet-derived growth factor alpha receptor (PDGFRA)-mutant gastrointestinal stromal tumor (GIST), and to compare the clinical values of the Zhongshan method of benign and malignant evaluation with the modified National Institutes of Health (NIH) risk stratification. <b>Methods:</b> A total of 119 cases of GIST with PDGFRA mutation who underwent surgical resection at Zhongshan Hospital, Fudan University from 2009 to 2020 were collected. The clinicopathological data, follow-up records, and subsequent treatment were reviewed and analyzed statistically. <b>Results:</b> There were 79 males and 40 females. The patients ranged in age from 25 to 80 years, with a median age of 60 years. Among them, 115 patients were followed up for 1-154 months, and 13 patients progressed to disease. The 5-year disease-free survival (DFS) and overall survival (OS) were 90.1% and 94.1%, respectively. According to the modified NIH risk stratification, 8 cases, 32 cases, 38 cases, and 35 cases were very-low risk, low risk, intermediate risk, and high risk, and 5-year DFS were 100.0%, 95.6%, 94.3%, and 80.5%, respectively. There was no significant difference in prognosis among the non-high risk groups, only the difference between high risk and non-high risk groups was significant (<i>P</i>=0.029). However, the 5-year OS was 100.0%, 100.0%, 95.0% and 89.0%, and there was no difference (<i>P</i>=0.221). According to the benign and malignant evaluation Zhongshan method, 43 cases were non-malignant (37.4%), 56 cases were low-grade malignant (48.7%), 9 cases were moderately malignant (7.8%), and 7 cases were highly malignant (6.1%). The 5-year DFS were 100.0%, 91.7%, 77.8%, 38.1%, and the difference was significant (<i>P</i><0.001). The 5-year OS were 100.0%, 97.5%, 77.8%, 66.7%, the difference was significant (<i>P</i><0.001). <b>Conclusions:</b> GIST with PDGFRA gene mutation shows a broad range of biological behavior, ranging from benign to highly malignant. According to the Zhongshan method, non-malignant and low-grade malignant tumors are common, the prognosis after surgery is good, while the fewer medium-high malignant tumors showed poor prognosis after surgical resection. The overall biological behavior of this type of GIST is relatively inert, which is due to the low proportion of medium-high malignant GIST. The modified NIH risk stratification may not be effective in risk stratification for PDGFRA mutant GIST.</p>","PeriodicalId":35997,"journal":{"name":"中华病理学杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Reappraisals of biological behaviors of PDGFRA mutant gastrointestinal stromal tumor].\",\"authors\":\"W Yuan, W Huang, L Ren, H Y Liang, S Y Dong, X Y Du, C Xu, Y Fang, K T Shen, Y Y Hou\",\"doi\":\"10.3760/cma.j.cn112151-20230908-00153\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objective:</b> To investigate the biological behavior spectrum of platelet-derived growth factor alpha receptor (PDGFRA)-mutant gastrointestinal stromal tumor (GIST), and to compare the clinical values of the Zhongshan method of benign and malignant evaluation with the modified National Institutes of Health (NIH) risk stratification. <b>Methods:</b> A total of 119 cases of GIST with PDGFRA mutation who underwent surgical resection at Zhongshan Hospital, Fudan University from 2009 to 2020 were collected. The clinicopathological data, follow-up records, and subsequent treatment were reviewed and analyzed statistically. <b>Results:</b> There were 79 males and 40 females. The patients ranged in age from 25 to 80 years, with a median age of 60 years. Among them, 115 patients were followed up for 1-154 months, and 13 patients progressed to disease. The 5-year disease-free survival (DFS) and overall survival (OS) were 90.1% and 94.1%, respectively. According to the modified NIH risk stratification, 8 cases, 32 cases, 38 cases, and 35 cases were very-low risk, low risk, intermediate risk, and high risk, and 5-year DFS were 100.0%, 95.6%, 94.3%, and 80.5%, respectively. There was no significant difference in prognosis among the non-high risk groups, only the difference between high risk and non-high risk groups was significant (<i>P</i>=0.029). However, the 5-year OS was 100.0%, 100.0%, 95.0% and 89.0%, and there was no difference (<i>P</i>=0.221). According to the benign and malignant evaluation Zhongshan method, 43 cases were non-malignant (37.4%), 56 cases were low-grade malignant (48.7%), 9 cases were moderately malignant (7.8%), and 7 cases were highly malignant (6.1%). The 5-year DFS were 100.0%, 91.7%, 77.8%, 38.1%, and the difference was significant (<i>P</i><0.001). The 5-year OS were 100.0%, 97.5%, 77.8%, 66.7%, the difference was significant (<i>P</i><0.001). <b>Conclusions:</b> GIST with PDGFRA gene mutation shows a broad range of biological behavior, ranging from benign to highly malignant. According to the Zhongshan method, non-malignant and low-grade malignant tumors are common, the prognosis after surgery is good, while the fewer medium-high malignant tumors showed poor prognosis after surgical resection. The overall biological behavior of this type of GIST is relatively inert, which is due to the low proportion of medium-high malignant GIST. The modified NIH risk stratification may not be effective in risk stratification for PDGFRA mutant GIST.</p>\",\"PeriodicalId\":35997,\"journal\":{\"name\":\"中华病理学杂志\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华病理学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/cma.j.cn112151-20230908-00153\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华病理学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112151-20230908-00153","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的研究血小板衍生生长因子α受体(PDGFRA)突变型胃肠间质瘤(GIST)的生物学行为谱,并比较中山良恶性评价法与美国国立卫生研究院(NIH)改良风险分层法的临床价值。研究方法收集2009年至2020年期间在复旦大学附属中山医院接受手术切除的119例PDGFRA突变的GIST病例。对临床病理数据、随访记录和后续治疗进行回顾性统计分析。结果男性 79 例,女性 40 例。患者年龄从 25 岁到 80 岁不等,中位年龄为 60 岁。其中 115 名患者接受了 1-154 个月的随访,13 名患者病情恶化。5年无病生存率(DFS)和总生存率(OS)分别为90.1%和94.1%。根据修改后的 NIH 风险分层,8 例、32 例、38 例和 35 例分别为极低风险、低风险、中度风险和高风险,5 年无病生存率分别为 100.0%、95.6%、94.3% 和 80.5%。非高风险组之间的预后无明显差异,只有高风险组和非高风险组之间的差异有显著性(P=0.029)。但5年生存率分别为100.0%、100.0%、95.0%和89.0%,无差异(P=0.221)。根据中山法进行良恶性评估,43 例为非恶性(37.4%),56 例为低度恶性(48.7%),9 例为中度恶性(7.8%),7 例为高度恶性(6.1%)。5年生存率分别为100.0%、91.7%、77.8%和38.1%,差异显著(PPConclusions:PDGFRA基因突变的GIST表现出从良性到高度恶性的广泛生物学行为。根据中山法,非恶性和低度恶性肿瘤常见,手术后预后良好,而较少的中高度恶性肿瘤手术切除后预后较差。这类 GIST 的整体生物学行为相对惰性,这是由于中高度恶性 GIST 的比例较低。修改后的 NIH 风险分层可能对 PDGFRA 突变型 GIST 的风险分层无效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[Reappraisals of biological behaviors of PDGFRA mutant gastrointestinal stromal tumor].

Objective: To investigate the biological behavior spectrum of platelet-derived growth factor alpha receptor (PDGFRA)-mutant gastrointestinal stromal tumor (GIST), and to compare the clinical values of the Zhongshan method of benign and malignant evaluation with the modified National Institutes of Health (NIH) risk stratification. Methods: A total of 119 cases of GIST with PDGFRA mutation who underwent surgical resection at Zhongshan Hospital, Fudan University from 2009 to 2020 were collected. The clinicopathological data, follow-up records, and subsequent treatment were reviewed and analyzed statistically. Results: There were 79 males and 40 females. The patients ranged in age from 25 to 80 years, with a median age of 60 years. Among them, 115 patients were followed up for 1-154 months, and 13 patients progressed to disease. The 5-year disease-free survival (DFS) and overall survival (OS) were 90.1% and 94.1%, respectively. According to the modified NIH risk stratification, 8 cases, 32 cases, 38 cases, and 35 cases were very-low risk, low risk, intermediate risk, and high risk, and 5-year DFS were 100.0%, 95.6%, 94.3%, and 80.5%, respectively. There was no significant difference in prognosis among the non-high risk groups, only the difference between high risk and non-high risk groups was significant (P=0.029). However, the 5-year OS was 100.0%, 100.0%, 95.0% and 89.0%, and there was no difference (P=0.221). According to the benign and malignant evaluation Zhongshan method, 43 cases were non-malignant (37.4%), 56 cases were low-grade malignant (48.7%), 9 cases were moderately malignant (7.8%), and 7 cases were highly malignant (6.1%). The 5-year DFS were 100.0%, 91.7%, 77.8%, 38.1%, and the difference was significant (P<0.001). The 5-year OS were 100.0%, 97.5%, 77.8%, 66.7%, the difference was significant (P<0.001). Conclusions: GIST with PDGFRA gene mutation shows a broad range of biological behavior, ranging from benign to highly malignant. According to the Zhongshan method, non-malignant and low-grade malignant tumors are common, the prognosis after surgery is good, while the fewer medium-high malignant tumors showed poor prognosis after surgical resection. The overall biological behavior of this type of GIST is relatively inert, which is due to the low proportion of medium-high malignant GIST. The modified NIH risk stratification may not be effective in risk stratification for PDGFRA mutant GIST.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
中华病理学杂志
中华病理学杂志 Medicine-Medicine (all)
CiteScore
1.00
自引率
0.00%
发文量
10377
期刊介绍:
期刊最新文献
[Advances in pathological diagnostic scoring systems and specific immune markers of adrenocortical carcinoma]. [Angiomatosis of the breast: a clinicopathological analysis of six cases]. [Application value of immunohistochemistry INSM1 combined with periodic acid-Schiff stain double staining in glandular and neuroendocrine amphicrine carcinoma in the digestive tract]. [Biological characteristics of triple negative breast cancer with low expression of HER2]. [Brenner tumor of the vagina: report of a case].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1